<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04937699</url>
  </required_header>
  <id_info>
    <org_study_id>2021-MATE-01</org_study_id>
    <nct_id>NCT04937699</nct_id>
  </id_info>
  <brief_title>MonotherApy of Low-does TicagrElor After Percutaneous Coronary Intervention</brief_title>
  <acronym>MATE</acronym>
  <official_title>Efficacy and Safety of Sequential Single Antiplatelet Therapy of Low-dose Ticagrelor and Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention With Acute Coronary Syndrome and High Bleeding Risk</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second Affiliated Hospital, School of Medicine, Zhejiang University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The MATE study is a randomized, multicenter, open-label, investigator-initiated clinical&#xD;
      trial aimed to evaluate efficacy and safety of sequential single antiplatelet therapy of&#xD;
      low-dose Ticagrelor and clopidogrel in patients with acute coronary syndrome (ACS) and high&#xD;
      bleeding risk after coronary intervention. Eligible patients will be randomized at 1:1 ratio&#xD;
      after PCI, into receiving standard-dose ticagrelor DAPT (SD.T) for 12months , or low-dose&#xD;
      ticagrelor DAPT for only 1 month, followed by 5 months of low-dose ticagrelor monotherapy,&#xD;
      and further de-escalated monotherapy of clopidogrel for another 6 months(LD.T).&#xD;
&#xD;
      The current study is to observe whether the low-does potent P2Y12 inhibitor can largely&#xD;
      reduce clinical-relevant bleeding versus dual antiplatelet therapy, while keep non-inferior&#xD;
      on thrombotic risk in ACS patients with high bleeding risk.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Compared with clopidogrel, ticagrelor inhibit platelet aggregation faster and stronger, and&#xD;
      significantly reduce the risk of cardiovascular and cerebrovascular adverse events. In recent&#xD;
      years, it has been given the strongest recommendation for antiplatelet therapy in ACS&#xD;
      patients. Nevertheless, it was shown that excessive bleeding events significantly affect its&#xD;
      antithrombotic advantage and only by downgrading regimen to improve safety can we seek the&#xD;
      maximum net clinical benefit, especially in people at high risk of bleeding. However, there&#xD;
      are still huge controversies regarding the degree or timing of the downgrading regimen.&#xD;
&#xD;
      The current study analyzes in detail the advantages and limitations of the existing research,&#xD;
      and makes a groundbreaking reform from the following three aspects: First, the Degree. A&#xD;
      series of studies have shown that compared with standard-does ticagrelor, low-does&#xD;
      ticagrelor(60mg) has nearly the same pharmacodynamic level on platelet function inhibition in&#xD;
      patients of either healthy volunteers, or stable angina and ACS. Therefore, low-does&#xD;
      ticagrelor with aspirin should be the starting point but not the end point of down-degrading.&#xD;
      On this basis, this study for the first time suggest the monotherapy of low-dose ticagrelor&#xD;
      in patients with high bleeding risk. Second, the Timing. It has been shown that&#xD;
      ticagrelor-related bleeding events mainly happened in the first 3-4 months after PCI. This&#xD;
      stage should not be a &quot;forbidden zone&quot; for all patients. In the current study, monotherapy of&#xD;
      low-dose ticagrelor will be used right after PCI in patients excluding STEMI and left main,&#xD;
      to observe whether it is not inferior to the standard DAPT on antithrombotic efficacy.&#xD;
      Finally, the Combination. The 2nd generation drug-eluding stents and drug-coated balloons&#xD;
      significantly shortened the course of dual antiplatelet therapy after PCI. Most of relative&#xD;
      studies have set it to 6 months. Therefore, this study continue to downgrade to clopidogrel&#xD;
      monotherapy 6 months after PCI, maximizing the benefits of bleeding reduction on the basis of&#xD;
      meeting safety requirements.&#xD;
&#xD;
      In summary, the current project aimed at high-bleeding-risk people with ACS, taking full&#xD;
      advantage of powerful antiplatelet drug of ticagrelor, for the first time proposed a&#xD;
      de-escalated antiplatelet regimen of sequential monotherapy of low-dose ticagrelor and&#xD;
      clopidogrel. In this project, low-does ticagrelor will be used as early as 1 month after PCI,&#xD;
      and the strength of anti-platelet will be further downgraded 5 months later to clopidogrel&#xD;
      (75 mg) monotherapy till 1 year, which is supposed to achieve a better safety benefit and a&#xD;
      non-inferior efficacy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>NACCE</measure>
    <time_frame>12 months after randomization.</time_frame>
    <description>The primary endpoint of the trial is the time to first occurrence of all-cause death, non-fatal myocardial infarction, stroke or BARC Types 2, 3 or 5 bleeding (NACCE) within 12 months after randomization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MACCE</measure>
    <time_frame>12 months after randomization.</time_frame>
    <description>The secondary endpoint for ischemic outcome is the time to first occurrence of all-cause death, non-fatal myocardial infarction or stroke occurring 12 months after randomization.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>BARC types 2,3 or 5 bleeding</measure>
    <time_frame>12 months after randomization</time_frame>
    <description>The secondary endpoint for bleeding outcome is the time to first occurrence of BARC types 2,3 or 5 bleeding within 12 months after randomization.</description>
  </other_outcome>
  <other_outcome>
    <measure>Other ischemic outcomes</measure>
    <time_frame>12 months after randomization</time_frame>
    <description>the time to first occurrence of all-cause death, cardiovascular death,non-fatal myocardial infarction,ischemic stroke or clinically-driven revascularization within 12 months after randomization.</description>
  </other_outcome>
  <other_outcome>
    <measure>Other bleeding outcomes</measure>
    <time_frame>12 months after randomization</time_frame>
    <description>the time to first occurrence of Any bleeding, or BARC types 3 or 5 bleeding within 12 months after randomization.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2856</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <condition>Percutaneous Coronary Intervention</condition>
  <condition>High Bleeding Risk</condition>
  <arm_group>
    <arm_group_label>Standard-Does Ticagrelor plus aspirin (SD.T+A)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be randomized after PCI, and receive standard-does ticagrelor plus aspirin in this arm as followed:&#xD;
Ticagrelor 90mg bid+Aspirin 100mg qd for 12months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-Does Ticagrelor monotherapy (LD.T)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be randomized after PCI, and receive low-does ticagrelor plus aspirin for the first month and switch to low-does ticagrelor monotherapy in the following 5 months, and then further de-escalated to clopidogrel monotherapy till 1 year in this arm as followed:&#xD;
Ticagrelor 60mg bid+Aspirin 100mg qd for 1 month; Ticagrelor 60mg bid, for 5 months; clopidogrel 75mg qd, for 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard-Does Ticagrelor plus aspirin</intervention_name>
    <description>ticagrelor 90mg bid plus aspirin 100mg qd, for 12months after randomization</description>
    <arm_group_label>Standard-Does Ticagrelor plus aspirin (SD.T+A)</arm_group_label>
    <other_name>SD.T+A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low-Does Ticagrelor monotherapy</intervention_name>
    <description>Ticagrelor 60mg bid+Aspirin 100mg qd for 1 month after randomization, then ticagrelor 60mg bid for 5 months; clopidogrel 75mg qd, for another 6 months.</description>
    <arm_group_label>Low-Does Ticagrelor monotherapy (LD.T)</arm_group_label>
    <other_name>LD.T</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18-80 years old;&#xD;
&#xD;
          2. Acute coronary syndrome was diagnosed upon admission;&#xD;
&#xD;
          3. Must meet at least one of the following high-risk clinical criteria for bleeding:&#xD;
&#xD;
               1. Female&#xD;
&#xD;
               2. Age ≥65 years old&#xD;
&#xD;
               3. Hemoglobin≤110g/L&#xD;
&#xD;
               4. Diabetes treated with medications (oral drugs or subcutaneous insulin injections)&#xD;
&#xD;
               5. eGFR&lt;60 ml/min/1.73m2 (MRDR formula)&#xD;
&#xD;
          4. Implant a second-generation drug-eluting stent&#xD;
&#xD;
          5. Intended treatment with dual antiplatelet therapy (aspirin + ticagrelor) after the&#xD;
             procedure for at least 12 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Implanted with first-generation DES or bioabsorbable stent(s) during hospitalization;&#xD;
&#xD;
          2. Patients with active pathological bleeding (such as peptic ulcer or intracranial&#xD;
             hemorrhage);&#xD;
&#xD;
          3. Previous drug-related bleeding requiring medications within 12 months;&#xD;
&#xD;
          4. High potential risk of major bleeding, such as acute or chronic gastrointestinal&#xD;
             ulcers or other gastrointestinal diseases, malignant tumors, etc.;&#xD;
&#xD;
          5. Previous stroke;&#xD;
&#xD;
          6. Thrombolytic therapy within 24 hours of coronary intervention;&#xD;
&#xD;
          7. Planned surgery within 1 year;&#xD;
&#xD;
          8. Planned coronary revascularization (surgical or percutaneous) within 90 days&#xD;
&#xD;
          9. Allergic to ticagrelor, clopidogrel or aspirin and any excipients;&#xD;
&#xD;
         10. Inability to tolerate 12-month DAPT (ticagrelor+aspirin) for any reason;&#xD;
&#xD;
         11. Cardiogenic shock or hemodynamic instability;&#xD;
&#xD;
         12. Diagnosed as active hepatitis or liver cirrhosis upon admission;&#xD;
&#xD;
         13. Estimated survival time&lt;12 months&#xD;
&#xD;
         14. Suffer from a known serious progressive disease (e.g. progressive cancer, chronic&#xD;
             obstructive lung disease, etc.;) or extremely exhausted;&#xD;
&#xD;
         15. Hemoglobin &lt;90g/L;&#xD;
&#xD;
         16. Platelet count&lt;100×109 pcs/L;&#xD;
&#xD;
         17. Dialysis-dependent renal failure；&#xD;
&#xD;
         18. Required use of oral anticoagulation (warfarin or other factor II or factor X&#xD;
             inhibitors);&#xD;
&#xD;
         19. Pregnant or plan to be pregnant within 1 year;&#xD;
&#xD;
         20. Any condition that may interfere with any study procedures, such as dementia,&#xD;
             immobility, alcohol use, etc;&#xD;
&#xD;
         21. Participating in any other clinical trial of an investigational drug or device that&#xD;
             has not met its primary endpoint.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yong Sun, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Second Affiliated Hospital, School of Medicine, Zhejiang University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Changling Li</last_name>
    <phone>86 0571-87783759</phone>
    <email>HREC2013@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Heyang Wang, MD</last_name>
    <phone>+86 0571 89713104</phone>
    <email>whysmmu@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>2nd Affiliated Hospital, School of Medicine at Zhejiang University</name>
      <address>
        <city>Hanzhou</city>
        <state>Zhejiang</state>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Changling Li</last_name>
      <phone>0571-87783759</phone>
      <email>HREC2013@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Heyang Wang, MD</last_name>
      <phone>0571-87783759</phone>
      <email>whysmmu@126.com</email>
    </contact_backup>
    <investigator>
      <last_name>Changling Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jun Jiang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Levine GN, Jeong YH, Goto S, Anderson JL, Huo Y, Mega JL, Taubert K, Smith SC Jr. Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. Nat Rev Cardiol. 2014 Oct;11(10):597-606. doi: 10.1038/nrcardio.2014.104. Epub 2014 Aug 26. Review.</citation>
    <PMID>25154978</PMID>
  </reference>
  <results_reference>
    <citation>Gurbel PA, Bliden KP, Butler K, Tantry US, Gesheff T, Wei C, Teng R, Antonino MJ, Patil SB, Karunakaran A, Kereiakes DJ, Parris C, Purdy D, Wilson V, Ledley GS, Storey RF. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation. 2009 Dec 22;120(25):2577-85. doi: 10.1161/CIRCULATIONAHA.109.912550. Epub 2009 Nov 18.</citation>
    <PMID>19923168</PMID>
  </results_reference>
  <results_reference>
    <citation>Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA; PLATO Investigators, Freij A, Thorsén M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009 Sep 10;361(11):1045-57. doi: 10.1056/NEJMoa0904327. Epub 2009 Aug 30.</citation>
    <PMID>19717846</PMID>
  </results_reference>
  <results_reference>
    <citation>Authors/Task Force members, Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Jüni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014 Oct 1;35(37):2541-619. doi: 10.1093/eurheartj/ehu278. Epub 2014 Aug 29.</citation>
    <PMID>25173339</PMID>
  </results_reference>
  <results_reference>
    <citation>Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Ting HH, O'Gara PT, Kushner FG, Ascheim DD, Brindis RG, Casey DE Jr, Chung MK, de Lemos JA, Diercks DB, Fang JC, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao DX. 2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention and the 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. J Am Coll Cardiol. 2016 Mar 15;67(10):1235-1250. doi: 10.1016/j.jacc.2015.10.005. Epub 2015 Oct 21. Review. Erratum in: J Am Coll Cardiol. 2016 Mar 29;67(12):1506.</citation>
    <PMID>26498666</PMID>
  </results_reference>
  <results_reference>
    <citation>Wu B, Lin H, Tobe RG, Zhang L, He B. Ticagrelor versus clopidogrel in East-Asian patients with acute coronary syndromes: a meta-analysis of randomized trials. J Comp Eff Res. 2018 Mar;7(3):281-291. doi: 10.2217/cer-2017-0074. Epub 2017 Nov 2.</citation>
    <PMID>29094604</PMID>
  </results_reference>
  <results_reference>
    <citation>Wang HY, Li Y, Xu XM, Li J, Han YL. Impact of Baseline Bleeding Risk on Efficacy and Safety of Ticagrelor versus Clopidogrel in Chinese Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. Chin Med J (Engl). 2018 Sep 5;131(17):2017-2024. doi: 10.4103/0366-6999.239306.</citation>
    <PMID>30127210</PMID>
  </results_reference>
  <results_reference>
    <citation>Li P, Gu Y, Yang Y, Chen L, Liu J, Gao L, Qin Y, Cai Q, Zhao X, Wang Z, Ma L. Low-dose ticagrelor yields an antiplatelet efficacy similar to that of standard-dose ticagrelor in healthy subjects: an open-label randomized controlled trial. Sci Rep. 2016 Aug 24;6:31838. doi: 10.1038/srep31838.</citation>
    <PMID>27554803</PMID>
  </results_reference>
  <results_reference>
    <citation>Orme RC, Parker WAE, Thomas MR, Judge HM, Baster K, Sumaya W, Morgan KP, McMellon HC, Richardson JD, Grech ED, Wheeldon NM, Hall IR, Iqbal J, Barmby D, Gunn JP, Storey RF. Study of Two Dose Regimens of Ticagrelor Compared with Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention for Stable Coronary Artery Disease (STEEL-PCI). Circulation. 2018 Jun 21. pii: CIRCULATIONAHA.118.034790. doi: 10.1161/CIRCULATIONAHA.118.034790. [Epub ahead of print]</citation>
    <PMID>29930021</PMID>
  </results_reference>
  <results_reference>
    <citation>Park DW, Lee PH, Jang S, Lim HS, Kang DY, Lee CH, Ahn JM, Yun SC, Park SW, Park SJ. Effect of Low-Dose Versus Standard-Dose Ticagrelor and Clopidogrel on Platelet Inhibition in Acute Coronary Syndromes. J Am Coll Cardiol. 2018 Apr 10;71(14):1594-1595. doi: 10.1016/j.jacc.2018.02.010.</citation>
    <PMID>29622168</PMID>
  </results_reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 16, 2021</study_first_submitted>
  <study_first_submitted_qc>June 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 24, 2021</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>low-does ticagrelor</keyword>
  <keyword>monotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The deidentified data will be shared after publication of first manuscript</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Data will be available within 12 months of study completion.</ipd_time_frame>
    <ipd_access_criteria>Data access requests will be reviewed by an external Independent Review Panel. Requestors will be required to sign a Data Access Agreement</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

